Do you want to read an article? Please log in or register.
Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis
Lung Cancer
Related content
Lung Cancer
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC
Clin Lung Cancer
Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C
doi: 10.1016/j.cllc.2025.05.007
RECOMMENDED
Lung Cancer
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lee J, Kim M, Han HJ, Kim S, Suh HS
doi: 10.1016/j.lungcan.2025.108682
RECOMMENDED
Lung Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
Lung Cancer
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
Semin Oncol
Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A
doi: 10.1016/j.seminoncol.2025.152431
Lung Cancer
Immune Checkpoint Inhibitor Without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A Real-World Retrospective Study
Clin Lung Cancer
Gao M, Nie Y, Wang T, Jing F, Zhang F, Tao H, Ma J, Wang L, Hu Y
doi: 10.1016/j.cllc.2025.08.011
Lung Cancer
Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor
Lung Cancer
Iso H, Ariyasu R, Fujishima S, Ito M, Nibuya K, Sugai M, Tsugitomi R, Amino Y, Uchibori K, Yanagitani N, Ninomiya H, Seike M, Nishio M
doi: 10.1016/j.lungcan.2025.108631
Lung Cancer
Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors
Clin Lung Cancer
Klein M, Watson D, Castro M, Kapoor S, Nair PR, Rajagopalan S, Qin H, Glaser M, Westanmo A, Lala DA, Kumar A, Chauhan J, G P, Ullal YS, Kulkarni S, Narvekar Y, Ghosh A, Tyagi A, Patil M, Macpherson MD, Wingrove JA, Patil T, Aggarwal C, Ganti AK
doi: 10.1016/j.cllc.2025.10.021
RECOMMENDED
Lung Cancer
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Clin Lung Cancer
Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A
doi: 10.1016/j.cllc.2025.12.007
RECOMMENDED
Lung Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4